to date. In the event that BHCP and the NPC are unable to agree upon the appointment of a mutually agreeable successor Claims Administrator, BHCP’s counsel and the NPC will each present two
to date. In the event that NPC and Organon are unable to agree upon the appointment of a mutually agreeable successor Claims Administrator, NPC and Organon’s counsel will each present two
to date. Cumulative costs to date of report will be reported for each phase.
to date. In the event that PSRC and Takeda are unable to agree upon the appointment of a mutually agreeable successor Claims Administrator, PSRC and Takeda’s counsel will each present two
to date. In the event that PNC and Daiichi Sankyo are unable to agree upon the appointment of a mutually agreeable successor Claims Administrator, PNC and Daiichi Sankyo’s counsel will each present two (2) candidates to the MDL Court.
to date. The Person who serves as the Claims Administrator under this Agreement shall be the same Person who serves in such capacity under the GMB Settlement Agreement.
to date. In so far as the interim report demonstrates that the beneficiary has used at least 70% of the amount of first pre-financing payment, the interim report must be considered as a request for a further pre-financing payment and must specify the amount requested up to EUR … corresponding to 40% the total maximum amount specified in Article I.3.
to date the Board of Directors has only approved this tender offer. The Board of Directors may, but is not obligated to, approve any subsequent tender offers, in aggregate amounts and for such prices as the Board of Directors may determine from time to time. There can be no assurance regarding the size of such tender offers, the price at which they will be conducted or that any of these subsequent tenders will occur at all. If they do not occur, this Offer may be your last opportunity to tender your Interest to the Fund. See Section 6 of this Offer to Purchase.
to date. The Editor-in-Chief, I/We, the undersigned author(s) of the manuscript entitled……………………………………………………………. ............................................................................................................………………………………………………………… ……………………………………...................... hereby declare that the above mentioned manuscript which is submitted for publication in the International Journal of Pharmaceutical Technology and Biotechnology (IJPTB) under my/our authorship has not been published or considered for publication elsewhere. I/We have reviewed the final version of the manuscript and approve it for publication. I undertake that scientific data and information has not been copied from the other published articles. Furthermore I/We attest that I/We shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested. All Authors agree that the contents of the manuscript are confidential and will not be copyrighted, submitted, or published elsewhere, in any language, while acceptance by the Journal is under consideration and after publication in International Journal of Pharmaceutical Technology and Biotechnology (IJPTB). I/We, as author/authors, hereby agree to transfer to International Journal of Pharmaceutical Technology and Biotechnology (IJPTB) all rights, including those pertaining to electronic forms and transmissions, under existing copyright laws. In connection with this assignment, the Author acknowledges that International Journal of Pharmaceutical Technology and Biotechnology (IJPTB) will have the right to print, publish, create derivative works, and sell the work throughout the world, all rights in and to all revisions or versions or subsequent editions of the work in all languages and media throughout the world and shall be the sole owner of the copyright in the work throughout the world. I/we also agree to the authorship of the article in the following sequence:
to date. Name of Landlord............................................................ Telephone: .......................................................................................... Payments to............................................................................................................... ........................... Amount: $...................................
